Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 10
Submit an article Journal homepage
833
Views
6
CrossRef citations to date
0
Altmetric
Editorial

Vaccinating against Japanese encephalitis virus: what have we learned from recent clinical trials?

Katrin Dubischar-Kastner Intercell AG, Campus Vienna Biocenter #3, FB-NR. 166438 M 1030 Vienna HG, Wien, Austria; Intercell AG, Campus Vienna Biocenter #3, FB-NR. 166438 M 1030 Vienna HG, Wien, Austria
&
Niranjan Kanesa-thasan Novartis Vaccines and Diagnostics Inc. 350 Massachusetts Avenue MS-170F, Cambridge MA 02139, USA. [email protected]; Novartis Vaccines and Diagnostics Inc. 350 Massachusetts Avenue MS-170F, Cambridge MA 02139, USA. [email protected]
Pages 1159-1161 | Published online: 09 Jan 2014

References

  • Campbell GL, Hills SL, Fischer M et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull. World Health Organ. 89(10), 766ndash;774 (2011).
  • Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev. Vaccines 10(3), 355ndash;364 (2011).
  • Daly J, Solomon T. Japanese encephalitis virus. In: The Immunological Basis for Immunization Series (Module 13). WHO Press, Geneva, Switzerland (2010).
  • Schiøler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst. Rev. 3, CD004263 (2007).
  • Dubischar-Kastner K, Kadlecek V, Eder S et al. Safety and immunogenicity of the inactivated Japanese encephalitis vaccine Ixiaro®, IC51, in Filipino children aged 2 months to < 18 years. Presented at: 9th Asia Pacific Travel Health Conference, Singapore, 2–5 May 2012.
  • Dubischar-Kastner K, Hatzenbichler E, Cramer J et al. Interim safety and immunogenicity data for the inactivated Japanese encephalitis vaccine Ixiaro®, IC51, in children from JE non-endemic countries. Presented at: 4th Northern European Conference on Travel Medicine, Dublin, Ireland, 6–8 June 2012.
  • Chanthavanich P, Limkittikul K, Sirivichayakul C et al. Two doses of inactivated chromatography purified Vero cell-derived Japanese encephalitis vaccine in children. Presented at: 7th World Congress of the World Society for Pediatric Infectious Disease (WSPID) 2011. Melbourne, Australia, 16–19 November 2011.
  • Okada K, Iwasa T, Namazue J, Akechi M, Ueda S; JE Vaccine Clinical Study Group. Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated) (JEBIK(®)V) in children. Vaccine 30(41), 5967ndash;5972 (2012).
  • Yokoye H. Newly Development of Vero cell-derived Japanese Encephalitis vaccine JEIMMUGEN (The Chemo-Sero-Therapeutic Research Institute, KAKETSUKEN). Presented at: 4th Annual World Vaccine Congress Asia 2010. Singapore, 10 June 2010.
  • Appaiahgari MB, Vrati S. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev. Vaccines 9(12), 1371ndash;1384 (2010).
  • WHO. Vaccine-preventable diseases and vaccines. In: International Travel and Health 2012 (Chapter 6). WHO Press, Geneva, Switzerland, 101ndash;103 (2012).
  • Chokephaibulkit K, Sirivichayakul C, Thisyakorn U et al. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr. Infect. Dis. J. 29(12), 1111ndash;1117 (2010).
  • Feroldi E, Thisyakorn U, Pancharoen C et al. Antibody persistence two years after single injection of live, attenuated, Japanese encephalitis chimeric virus vaccine at 12–24 months of age. Presented at: 7th World Congress of the World Society for Pediatric Infectious Disease (WSPID) 2011. Melbourne, Australia, 16–19 November 2011.
  • Woolpert T, Staples JE, Faix DJ et al. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine. Vaccine 30(20), 3090ndash;3096 (2012).
  • Erra E, Hervius Askling H, Rombo L et al. A single dose of Vero cell–derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines.Clin. Infect. Dis. 55(6), 825–834 (2012).
  • Takeshita N, Mizuno Y, Lim C.-K et al. Immunity to Japanese encephalitis and booster vaccine efficacy in Japanese travellers. Presented at: 12th Conference of the International Society of Travel Medicine (CISTM) 2011. Boston, MA, USA, 8–12 May 2011.
  • Schuller E, Klingler A, Dubischar-Kastner K, Dewasthaly S, Müller Z. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®). Vaccine 29(47), 8669ndash;8676 (2011).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.